Delving into the Latest Updates on Cardax Pharmaceuticals, Inc. with Synapse

Overview

Basic Info

Introduction

Cardax Pharmaceuticals is a company that specializes in creating small molecule therapies to address significant medical issues where oxidative stress and inflammation are contributing factors. These conditions include cardiovascular disease, hepatitis, macular degeneration, and various types of cancer. The company's unique compound derivatives are designed to be both effective and safe, with excellent oral bioavailability and tissue selectivity. Founded in 2006 by David G. Watumull and Samuelf Lockwood, Cardax Pharmaceuticals is based in Honolulu, Hawaii.

Tags

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

Astaxanthine is a polar carotenoid metabolite derived from a proprietary prodrug, Xancor, which aligns parallel with the membrane phospholipids exhibiting potent antioxidant, anti-inflammatory, and cell protective properties, although the precise mechanism of action is unknown. This prodrug is currently under development for hepatic, neurologic, and vascular disease indications. Considering established links between heart disease and stroke with platelets, coagulation cascade, and fibrinolysis, the aim of the study was to assess the effect of asthaxantine on human biomarkers of hemostasis. The rationale was to test a hypothesis that the drug may diminish activation of hemostasis, making it a potentially attractive addition to treat patients with vascular disease. In vitro effects of whole blood preincubation with escalating concentrations of asthaxantine (0.3 microM, 1 microM, 3 microM, 10 microM, 30 microM, and 100 microM) were assessed from 12 aspirin-naïve and eight aspirin-treated volunteers with multiple risk factors for vascular disease. A total of 25 biomarkers were measured, of which 12 were related to platelet function, 10 to coagulation, and three to fibrinolysis. Platelet aggregation induced by ADP, collagen, and arachidonic acid and expression of CD31, CD41, GP IIb/IIIa, CD51/61, P-selectin, CD63, CD107a, CD151+CD14, and CD154 were not affected. Coagulation indices such as aPTT, prothrombin time, thrombin time, fibrinogen, antithrombin III (antigen and activity), Protein C, Protein S (free and activity), and von Willebrand factor remained unchanged after incubation with astaxanthine. Fibrinolytic activity biomarkers such as plasminogen, D-dimer, and FDP were also not affected after in vitro pretreatment of blood samples with astaxanthine. In the projected subclinical (less than 1 microM), therapeutic (3 microM to 30 microM), and supratherapeutic concentration (100 microM), astaxanthine in vitro does not affect platelet, coagulation, or fibrinolytic indices in either aspirin-naïve or aspirin-treated subjects. These results are important for the assessment of the safety profile, but remain to be confirmed preclinically, in vivo, and ultimately in the clinic.

Synthesis and characterization of water-dispersible lycoxanthin derivatives

Author: Braun, Cristi ; Lockwood, Samuel F. ; Jackson, Henry L.

Epidemiol. studies support an association between consumption of carotenoid-rich foods and decreased risk of diseases such as various cancers and cardiovascular diseases.Most carotenoids lack appreciable solubility in water, limiting the exploration of their therapeutic potential.Previously, we have shown that the aqueous dispersibility of the xanthophyll carotenoids astaxanthin and lutein can be increased through derivatization.In the current study the total synthesis and characterization of the rare C40 lycopene xanthophyll lycoxanthin will be described.The preparation and characterization of a number of derivatives which exhibit increased water dispersibility over the parent lycoxanthin will also be discussed.

100 Deals associated with Cardax Pharmaceuticals, Inc.

Login to view more data

100 Translational Medicine associated with Cardax Pharmaceuticals, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Login to view more data